News Releases

Date	Title and Summary	View
Oct 10, 2018	Janssen Submits European Marketing Authorisation Application for Esketamine Nasal Spray for Treatment-Resistant Depression
Oct 09, 2018	NEW PHASE 3 DATA SHOW SINGLE DOSE OF STELARA® (USTEKINUMAB) INDUCES CLINICAL REMISSION AND RESPONSE IN ADULTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS
Oct 04, 2018	Janssen Announces Exclusive, Worldwide License Agreement with Arrowhead Pharmaceuticals to Develop and Commercialize a New Treatment for Chronic Hepatitis B Viral Infection
Oct 02, 2018	Johnson & Johnson Completes Divestiture of LifeScan to Platinum Equity NEW BRUNSWICK, N.J. , Oct. 2, 2018 /CNW/ -- Johnson & Johnson (NYSE: JNJ) today announced that it has completed the divestiture of its LifeScan business to Platinum Equity for approximately $2.1 billion . LifeScan, Inc. is a world leader in blood glucose monitoring and maker of the OneTouch ®
Sep 27, 2018	Janssen Elects Not to Continue Agreement with Geron for Imetelstat Janssen Elects Not to Continue Agreement with Geron for Imetelstat HORSHAM, Pa., Sept. 27, 2018 /PRNewswire/ -- Janssen Biotech, Inc. (Janssen) announced today its decision not to continue the collaboration and license agreement with Geron Corporation for imetelstat.
Sep 26, 2018	DePuy Synthes Expands Spine Portfolio with Nerve Assessment Platform Designed to Identify & Avoid Nerves During Spine Surgery
Sep 21, 2018	Janssen Announces Results of Esketamine Nasal Spray Phase 3 Study in Patients with Treatment-Resistant Depression TITUSVILLE, N.J. , Sept. 21, 2018 /PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson today announced results from a Phase 3 clinical study of the investigational product esketamine nasal spray in patients with treatment-resistant depression.
Sep 19, 2018	Johnson & Johnson to Host Investor Conference Call on Third-Quarter Results NEW BRUNSWICK, N.J. , Sept. 19, 2018 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) will host a conference call for investors at 8:30 a.m. (Eastern Time) on Tuesday, October 16 th , to review third-quarter results. Joseph J. Wolk , Executive Vice President, Chief Financial Officer and Christopher
Sep 18, 2018	Janssen Submits New Drug Application to U.S. FDA Seeking Approval of Erdafitinib for the Treatment of Metastatic Urothelial Cancer
Sep 11, 2018	Health-Related Quality of Life Maintained with Addition of ERLEADA® to Androgen Deprivation Therapy for Patients with Non-Metastatic Castration-Resistant Prostate Cancer